SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-005787
Filing Date
2023-08-15
Accepted
2023-08-15 08:30:11
Documents
13
Period of Report
2023-08-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 32020
2 AMENDED AND RESTATED BYLAWS OF CNS PHARMACEUTICALS, INC. cns_ex0301.htm EX-3.1 104167
  Complete submission text file 0001683168-23-005787.txt   337516

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20230811.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cnsp-20230811_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20230811_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3519
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

IRS No.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 231173286
SIC: 2834 Pharmaceutical Preparations